Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Quoin Pharmaceuticals, Ltd. American Depositary Shares

QNRX

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Last trade $3.54
Day change -$0.02 (-0.56%)
Day range $3.46 – $3.68
Volume 7,137
Market cap $17M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$17.1M
Price / earnings
—
Price / book
0.6×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.35×

Profitability

Earnings per share
-$4.08
Return on assets
-56.37%
Return on equity
-68.26%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.2×
Quick ratio
7.2×
Cash ratio
2.11×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.82M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QNRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.27M$1.85M$1.7M$1.42M$1.74M$1.74M$1.58M$1.35M
Research and development$2.66M$3.63M$3.43M$3.1M$2.28M$2.05M$2.37M$1.05M
Total operating expenses$4.92M$5.47M$5.13M$4.52M$4.02M$3.79M$3.96M$2.41M
Operating income-$4.92M-$5.47M-$5.13M-$4.52M-$4.02M-$3.79M-$3.96M-$2.41M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.87M-$5.37M-$5M-$4.35M-$3.95M-$3.7M-$3.81M-$2.31M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.87M-$5.37M-$5M-$4.35M-$3.95M-$3.7M-$3.81M-$2.31M
Net income attributable to common shareholders-$4.87M-$5.37M-$5M-$4.35M-$3.95M-$3.7M-$3.81M-$2.31M
EBITDA-$4.9M-$5.45M-$5.11M-$4.5M-$3.99M-$3.77M-$3.93M-$2.38M
Basic earnings per share-$0.97-$1.90-$1.77-$1.73-$6.71-$6.28-$6.50-$12.96
Diluted earnings per share-$0.97-$1.90-$1.77-$1.73-$6.71-$6.28-$6.50-$12.96

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Quoin (QNRX) Q2 Loss Beats Estimates

Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.

GlobeNewswire Inc.

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Quoin Pharmaceuticals announced highly positive interim data from its ongoing Netherton Syndrome clinical trials, with the first subject demonstrating marked improvements across all measured endpoints after 12 weeks of treatment with the company's QRX003 topical lotion. The company is optimistic about the therapy's potential to effectively treat this rare and debilitating skin disease.

GlobeNewswire Inc.

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.

GlobeNewswire Inc.

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 9, 20251-for-35reverse split
Jul 18, 20231-for-12reverse split
Aug 1, 20221-for-12.5reverse split
Sep 24, 20211-for-4reverse split
Oct 23, 20191-for-5reverse split